What you should know:
1. Omidria phenylephrine and ketorolac intraocular solution 1 percent/0.3 percent qualifies for separate payment retroactive to Oct. 1, 2020.
2. This is the first time Omidria is eligible under CMS’ payment policy for non-opioid pain management surgical drugs in the ASC.
3. Omidria is FDA-approved for use in cataract or lens replacement to prevent intraoperative pupil constriction and reduce postoperative ocular pain.
More articles on surgery centers:
10 recent ASC leadership moves
Virginia ASC takes infection prevention to new level — 3 insights
Surgery Partners goes all-in on cardiology — 5 quotes on its quarterly performance
